JDRF Comments on New Disease-Modifying Therapy Research Published in Lancet
November 09, 2023
November 09, 2023
NEW YORK, Nov. 9 (TNSres) -- JDRF, a non-profit dedicated to funding type 1 diabetes research, issued the following news release:
A paper published this month in Lancet Diabetes and Endocrinology showed that disease-modifying therapies preserve beta cell function via C-peptide and also have beneficial metabolic effects in new onset type 1 diabetes (T1D). The paper included initial results from the Trial Outcome Markers Initiative (TOMI), which combined data from 21 disease-modifying . . .
A paper published this month in Lancet Diabetes and Endocrinology showed that disease-modifying therapies preserve beta cell function via C-peptide and also have beneficial metabolic effects in new onset type 1 diabetes (T1D). The paper included initial results from the Trial Outcome Markers Initiative (TOMI), which combined data from 21 disease-modifying . . .